Pharmacokinetics of Envarsus in pediatric kidney transplant recipients – phase 1 pilot conversion study
Introduction Tacrolimus is the standard immunosuppressant for pediatric kidney transplants and is routinely administered twice daily (BD‐tac). Envarsus (LCP‐tac), an extended‐release formulation, is approved for adults but not for pediatric patients. Methods We conducted a pilot open‐label phase 1 s...
Gespeichert in:
Veröffentlicht in: | Pediatric transplantation 2024-03, Vol.28 (2), p.e14703-n/a |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
Tacrolimus is the standard immunosuppressant for pediatric kidney transplants and is routinely administered twice daily (BD‐tac). Envarsus (LCP‐tac), an extended‐release formulation, is approved for adults but not for pediatric patients.
Methods
We conducted a pilot open‐label phase 1 study in stable pediatric kidney transplant recipients (age |
---|---|
ISSN: | 1397-3142 1399-3046 |
DOI: | 10.1111/petr.14703 |